Results
1 -
10 of
17
(Click
here to explore results)
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 6 D3 Receptor Agonists and Antagonists as Anti‐Parkinsonian Therapeutic Agents. Mark Johnson, Aloke Dutta
, 2013
, Pages 126-148
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 5 Pharmacologic Management of Dopaminergic‐Induced Dyskinesias in Parkinson’s Disease. Mildred D. Gottwald, Michael J. Aminoff
, 2013
, Pages 110-125
- Anti-aging Drugs: From Basic Research to Clinical Practice, CHAPTER 5 Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Ramón Cacabelos, Juan Carlos Carril, Oscar Teijido
, 2017
, Pages 75-141
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 3 Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows. Nicola Simola
, 2013
, Pages 61-82
- Emerging Drugs and Targets for Parkinson's Disease, Subject Index
, 2013
, Pages 390-402
- Coffee: Consumption and Health Implications, CHAPTER 7 Caffeine and Parkinson's Disease: From Molecular Targets to Epidemiology and Clinical Trials. Jiang-Fan Chen
, 2019
, Pages 171-195
- Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents, Chapter 3 Recent Developments in PET and SPECT Radioligands for CNS Imaging. David Alagille, Ronald M. Baldwin, Gilles D. Tamagnan
, 2012
, Pages 49-143
- Drug Discovery for Psychiatric Disorders, CHAPTER 13 Therapeutic Approaches to Bipolar Disorder. Moghis U. Ahmad, Shoukath M. Ali, Saifuddin Sheikh, Ateeq Ahmad, Imran Ahmad
, 2012
, Pages 333-356
- Drug Repurposing, Chapter 13 Intellectual Property Considerations. Hermann Mucke
, 2022
, Pages 264-279
- Mechanisms and Metal Involvement in Neurodegenerative Diseases, CHAPTER 3 Parkinson’s Disease: Involvement of Iron and Oxidative Stress. David T. Dexter
, 2013
, Pages 58-79